About Alltrna
Alltrna focuses on developing tRNA therapeutics to treat diseases caused by genetic mutations. Their main product involves engineered tRNAs that can recognize and read stop codons, which are errors in the genetic code that lead to the production of incomplete proteins. By delivering the correct amino acids, these tRNAs help restore the synthesis of full-length proteins, potentially addressing a wide range of diseases linked to nonsense mutations. Unlike other biotech companies, Alltrna is the first to explore the therapeutic potential of tRNA in this way, aiming to unlock new treatment options for patients with specific genetic disorders. The goal of Alltrna is to provide effective therapies that target the root causes of diseases, improving the quality of life for those affected.